RxDoctor Payments DataLook up a doctor →

James Lipstate, MD

Rheumatology · Lafayette, LANPI 1043260607

Payments from drug & device makers

$13,910in general payments, 2019–2025

Across 609 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Tandem Diabetes Care, Inc.$2K
  • GSK$820
  • UCB, Inc.$799
  • Novartis$680
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$1,70012%
  • Food & beverage$12,15487%
  • Education$560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,910 in reported general payments places this provider in the 55th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,708,672
Medicare patients
811
Services billed
168,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab281$2,041,487
Enbrel SureclickEtanercept172$1,350,185
RinvoqUpadacitinib153$1,017,928
Orencia ClickjectAbatacept82$475,526
Cosentyx Sensoready PenSecukinumab42$378,476
Cosentyx Sensoready (2 Pens)Secukinumab40$300,754
Actemra ActpenTocilizumab56$205,643
EnbrelEtanercept28$198,836
Taltz AutoinjectorIxekizumab25$172,247
Humira PenAdalimumab23$154,463
OtezlaApremilast25$143,802
Cosentyx Unoready PenSecukinumab13$119,754
LupkynisVoclosporin12$116,753
Xeljanz XrTofacitinib Citrate15$97,413
ActemraTocilizumab25$91,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,997$1,017,928153 claims
AmgenEnbrel, Otezla, Prolia$2,521$385,64178 claims
Aurinia Pharma U.S., Inc.Lupkynis$642$116,75312 claims
SanofiKevzara$229$79,68419 claims
GSKBenlysta$820$68,53614 claims
Radius Health, Inc.Tymlos$345$31,93412 claims
Medexus Pharma, Inc.Rasuvo$113$15,93328 claims
PfizerLyrica$377$7,40012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 88 rheumatology providers in Louisiana.

Other rheumatology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →